STK39 and WNK1 Are Potential Hypertension Susceptibility Genes in the BELHYPGEN Cohort by Persu, Alexandre et al.
Medicine®
OBSERVATIONAL STUDYSTK39 and WNK1 Are Potential Hypertension Susceptibility
Genes in the BELHYPGEN Cohort
Alexandre Persu, MD, PhD, Lucie Evenepoel, MS, Yu Jin, MD, PhD, Antonella Mendola, MS,
Ge´rard Ngueta, PhD, Wen-Yi Yang, MD, Damien Gruson, PhD, Sandrine Horman, PhD,
Jan A. Staessen, MD, PhD, and Miikka Vikkula, MD, PhD, on behalf of the BELHYPGEN ConsortiumEditor: Jose Vilela-Martin.
Received: September 11,
February 9, 2016.
From the Pole of Cardio
Recherche Expe´rimentale
Brussels, Belgium; Cardiol
taires Saint-Luc, Universi
Human Molecular Genetic
catholique de Louvain, Br
(YJ, W-YY, JAS), Rese
Epidemiology, KU Leuv
University of Leuven, Leu
Health Practices Research
Que´bec, Canada; Poˆle de
Nutrition, Institut de Rec
Universitaires Saint-Luc,
Belgium; Department of L
taires Saint-Luc, Universite´
Research and Developmen
Maastricht, The Netherland
Correspondence: Alexand
Universitaires Saint-Lu
Belgium (e-mail: alexa
These studies were partly s
aux chercheurs, to AP)
Scientifique) grant T.0
FNRS-Te´le´vie fellowsh
278249 EU-MASCAR
European Research C
EPLORE) and the Fond
Ministry of the Flemish
G.0880.13) supported
Belgium).
The authors have no confli
Copyright # 2016 Wolters
This is an open access ar
Attribution License 4.0, w
reproduction in any mediu
ISSN: 0025-7974
DOI: 10.1097/MD.0000000
Medicine  Volume 95Abstract: The serine/threonine kinase With-No-Lysine (K) Kinase 1
(WNK1) activates the thiazide-sensitive Naþ/Cl cotransporter through
phosphorylation of STE20/SPS1-related proline/alanine-rich kinase,
another serine/threonine kinase encoded by STK39. The aim of this
study was to look for association between WNK1 and STK39 gene
variants, and blood pressure (BP) and hypertension.
Seven hundred seventy-nine Caucasian hypertensive patients (HYP)
recruited in 6 academic centers from Belgium, and 906 normotensive
(NT) controls were genotyped for 5 single nucleotide polymorphisms—
rs3754777, rs6749447, rs35929607 (STK39), rs1468326, and rs765250
(WNK1)—using the Snapshot method.
The rare TT genotype at the rs3754777 locus (STK39) was over-
represented in HYP versus NT (7.3% vs 3.0%, P¼ 0.0002). In the whole
study population, the multivariable-adjusted odds ratio (OR) for having
hypertension associated with the TT genotype was 5.9 (95% confidence
interval: 2.2–15.6), and systolic BP was 10mm Hg higher in TT
compared with wild-type subjects (140.1 vs 130.4mm Hg,2015; revised: February 4, 2016; accepted:
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, Number 15, April 2016P¼ 0.002). Similarly, the AA genotype at the rs1468326 locus
(WNK1) was twice as frequent in HYP versus NT (5.5% vs 2.3%,
P< 0.0001), and associated with an increased adjusted OR of hyper-
tension (4.1; 1.5–11.7) and a higher systolic BP (139.8 vs 130.1mmHg,
P¼ 0.003). In the whole cohort, a dose-dependent increase in systolic
BP was observed according to the number of at-risk genotypes (0:
129.8mm Hg; 1: 133.0mm Hg; 2: 149.3mm Hg, P¼ 0.02).
Single nucleotide polymorphisms rs3754777 (STK39) and
rs1468326 (WNK1) were associated with hypertension and BP in our
multicenter Belgian case-control study, which supports the role of
STK39 and WNK1 as potential hypertension susceptibility genes.
Replication in different clinical settings and study of other candidate
loci belonging to the same molecular pathway is warranted.
(Medicine 95(15):e2968)
Abbreviations: BP = blood pressure, CRF = Case Report Form,
GWAS = genomewide association study, NCC = thiazide-sensitive
Naþ/Cl cotransporter, OR = odds ratio, SPAK = STE20/SPS1-
related proline/alanine-rich kinase, WNK1 = With-No-Lysine (K)
Kinase 1.
INTRODUCTION
H ypertension is a complex disease, influenced by multiplegenetic and environmental factors. Heritability of blood
pressure (BP) has been estimated to 30% to 55%.1 The loci so
far identified account for only a small proportion of this
heritability.2
A large body of evidence supports a crucial role for the
kidney in BP regulation and pathogenesis of essential hyper-
tension.1,3 In particular, several rare Mendelian forms of hy-
pertension are due to mutations of genes involved in sodium and
water reabsorption.4,5 Hence, it has been hypothesized that
genetic variants affecting ion channels, transporters, and regu-
latory proteins involved in these pathways may be at the origin
of more common forms of essential hypertension.
A genomewide association study (GWAS) performed in
Amish, and then replicated in several non-Amish populations
identified STK39 as a possible hypertension susceptibility
gene.6 STK39 encodes a serine/threonine kinase named
STE20/SPS1-related proline/alanine-rich kinase (SPAK),
which activates the thiazide-sensitive Naþ/Cl cotransporter
(NCC), expressed at the apical membrane of epithelial cells
lining the distal convoluted tubule by phosphorylation of
particular residues.7–10 In its turn, SPAK is activated through
phosphorylation by the serine/threonine ‘‘With-No-Lysine (K)
Kinase 1’’ (WNK1).7–10
In the current study, we took advantage of the BELHYP-
GEN cohort, including hypertensive patients (HYP) followed in
tertiary referral centers from Belgium11 to look for an associ-
ation between previously described genetic variants locatedwww.md-journal.com | 1
Persu et al Medicine  Volume 95, Number 15, April 2016within or in the vicinity of STK39 andWNK1, and hypertension
and BP level.
MATERIALS AND METHODS
Population
All Caucasian patients with essential hypertension seen at
the hypertension clinics of 6 Belgian University Hospitals (see
BELHYPGEN consortium) from November 2005 to April 2010
were eligible. In all patients, a standardized Case Report Form
(CRF) was completed, and blood samples were obtained for usual
blood analysis and DNA extraction. In addition to main demo-
graphic characteristics, information was obtained on cardiovas-
cular risk factors, target organ damage, previous cardiovascular
events, number and classes of antihypertensive drugs, as well as
lipid-lowering, antidiabetic, and antiplatelet medications. BP was
measured after 5 minutes of rest in the sitting position according
to the European Society of Hypertension guidelines.12 A mercury
sphygmomanometer was used in 5 centers and a validated
oscillometric device (Omron M4) in 1 center.
Controls were subjects with normal office BP (systolic BP
<140 mm Hg and diastolic BP <90 mm Hg) in the absence of
BP-lowering medications seen at the occupational health con-
sultation of the Cliniques Universitaires Saint-Luc and Uni-
versite´ catholique de Louvain (CESI, Louvain-en-Woluwe´,
Brussels). A simplified CRF and blood samples for DNA
extraction were obtained in all participants.
Both CRF and DNA samples were anonimized. A unique
ID number was used for both clinical and paraclinical infor-
mation, and DNA. The study was approved by the Ethics
Committees of the Cliniques Universitaires Saint-Luc and all
other participating university centers. All participants gave
written informed consent.
DNA Extraction
Genomic DNA was extracted from leukocytes contained in
the blood using the Wizard Genomic DNA Purification Kit
(Promega, Madison, Wisconsin, USA). Briefly, the red blood
cells, as well as the nuclei of the leukocytes, were lysed.
Subsequently, proteins were precipitated, followed by the pre-
cipitation of DNA using isopropanol. The DNA pellet was
washed with ethanol. Finally, DNA was rehydrated with the
DNA Rehydration Solution.
Genotyping
All subjects were genotyped for STK39 rs3754777,
rs6749447, and rs35929607, as well as for WNK1 rs1468326
and rs765250. The different single nucleotide polymorphisms
(SNPs) were sequenced using the SNaPshot minisequencing
assay (Applied Biosystems, Foster city, California, USA),
according to the manufacturer’s instructions. Twenty nano-
grams of DNA were used for PCR amplifications that were
performed using primers flanking the region containing the SNP
of interest. Subsequently, amplicons were cleaned by FastAP
Thermosensitive Alkaline Phosphatase (Fermentas, Waltham,
Massachusetts, USA) and Exonuclease I treatment (Thermo
Fisher Scientific, Waltham, Massachusetts, USA). A Forward or
Reverse primer with a 3-prime end just at the SNP-site was used
to perform a single-base extension reaction with fluorescently
labeled ddNTPs. The products were purified with the FastAP,
denatured using the Hi-Di Formamide, and run on an
ABI3130xl Genetic Analyzer (Applied Biosystems). The
analysis of the sequences was performed using the GeneMapper2 | www.md-journal.comSoftware (Applied Biosystems), which shows peaks of different
colors, reflecting the genotypes of the SNPs. Primers and
conditions are available on request.
Statistical Analysis
We used SAS, version 9.3, for database management and
statistical analysis; we compared means and proportions, using
ANOVA and the x2 statistic, respectively. We tested the Hardy-
Weinberg equilibrium using the SAS procedure PROC
ALLELE. We included in our models covariables with known
physiologic relevance for hypertension. We additionally
searched for possible covariables, using stepwise multiple
regression with P values for independent variables to enter
and stay in the models set at 0.15. For studies with hypertension
as outcome, we computed odds ratios (ORs) using logistic
regression model. In multivariable-adjusted analyses, we com-
puted OR adjusted for sex, age, body mass index (BMI), and
total number of antihypertensive drug classes. We considered
additive (BB vs AB vs AA) and recessive (BB vs AB þ AA)
genetic models.
RESULTS
Descriptive Analysis
The main characteristics of HYP and normotensive (NT)
controls are shown in Table 1. Characteristics specifically
collected in HYP but not in NT subjects are shown in
Table 2. Most HYP initially had moderate-to-severe hyperten-
sion, and were relatively well controlled under a median of 2
antihypertensive drug classes. Compared with controls, hyper-
tensive subjects had 30/16mm Hg higher average BP despite
antihypertensive treatment, they were 20 years older, had
significantly higher BMI, and reported more frequently a
familial history of early hypertension and cardiovascular dis-
ease. In contrast with HYP, no participant from the control
group had previous or current cardiovascular disease and only
84 (0.6%) reported diabetes mellitus.
Variants rs3754777 and rs1468326 were strongly associ-
ated with hypertension. A borderline significant association was
also found for rs7765250. The distribution of genotypes for the
2 remaining SNPs did not differ significantly between HYP and
NT subjects (Table 3). Accordingly, further studies were
focused on the effect of rs3754777 and rs1468326 on BP
and hypertension.
Association of SNP rs3754777 (STK39) With
Hypertension and BP
The distribution of genotypes of the rs3754777 SNP
located within STK39 was significantly different either in an
additive (P¼ 0.0002) or a recessive model (P< 0.0001), mainly
due to a 2-fold higher prevalence of the rare TT genotype in
hypertensive (7.3%) versus control subjects (3.0%) (Table 3).
Compared with CC patients, patients harboring the minor T
allele at the heterozygous or homozygous state had an OR of
hypertension of 1.1 (95% confidence interval [CI]: 0.9–1.4) and
2.7 (95% CI: 1.6–4.3), respectively. The association was even
more significant in a logistic regression model including age,
sex, BMI, and total number of antihypertensive drug classes
(OR CT vs CC: 2.1 [95% CI: 1.3–3.3]; TT vs CC: 5.9 [95% CI:
2.2–15.6]) (Figure 1A). Furthermore, in the whole data set
including both cases and controls, mean office systolic BP was
significantly higher in patients harboring the TT genotype
compared with CT and CC patients (Figure 1D).Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Main Characteristics of Cases and Controls Included in the BELHYPGEN Study
Hypertensive Patients Healthy Controls
Number 779 906
Age, y 56.9 14.0 36.6 11.4
Women, % 54 71

Systolic blood pressure, mm Hg 147.9 23.4 117.4 11.1
Diastolic blood pressure, mm Hg 87.3 13.0 71.4 8.0
Heart rate, bpm 69.9 11.9 69.8 8.6
Body mass index, kg/m2 28.3 5.1 23.4 3.7
Waist circumference, cm 97.3 15.1 79.9 10.5
Smoking, % 13.3 15.9
Type 2 diabetes, % 10.9 0.6

Lipid-lowering treatment, % 24.8 1.4
History of myocardial infarction, % 3.1 —
Myocardial revascularisation, % 4.2 —
Stroke, % 6.7 —
Familial history of hypertension, % 28.6 4.8

Familial history of CV diseases, % 21.2 9.4

Myocardial revascularisation included coronary bypass and/or coronary angioplasty. Familial history of hypertension was defined as hypertension
diagnosed before 50 years old in at least one first-degree relative. Familial history of cardiovascular disease was defined as cardio- or cerebrovascular
disease in at least one first-degree relative, before 55 years in men and before 65 years in women. Continuous data are indicated as mean standard
deviation.
CV¼ cardiovascular.
P< 0.0001.
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Hypertension and BP
Similarly, the distribution of genotypes of the WNK1
variant rs1468326 was significantly different in HYP and NTTABLE 2. Additional Characteristics of Hypertensive Patients Incl
Hypertension
Number of years since hypertension diagnosis
Systolic blood pressure level at the time of diagnosis, mm Hg
Diastolic blood pressure level at the time of diagnosis, mm Hg
Antihypertensive treatment
Antihypertensive treatment at inclusion
Mean number of antihypertensive drugs
Antihypertensive drug classes, %
Diuretics
Beta-blockers
Calcium-antagonists
Angiotensin-converting inhibitors
Angiotensin-1 receptor blockers
Alpha-blockers
Centrally acting drugs
Blood analysis
Estimated glomerular filtration rate (mL/min/1.73m2)
MDRD
CKD-EPI
Total cholesterol, mg/dL
LDL-cholesterol, mg/dL

HDL-cholesterol, mg/dL
CKD-EPI¼Chronic Kidney Disease Epidemiology Collaboration,
MDRD¼Modification of Diet in Renal Disease equation.
Calculated using the Friedewald formula. Continuous data are indicate
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.controls, both in an additive (P¼ 0.0009) and a recessive model
(P¼ 0.001), with a 2-fold increase in prevalence of the rare AA
genotype in HYP (5.5% vs 2.3%) (Table 3). Compared with CC
patients, the OR of being hypertensive was significantlyuded in BELHYPGEN Study
17.9 10.6
172.0 24.0
99.9 12.9
84.7%
1.9 1.4
44.5
44.9
34.3
32.8
27.6
3.3
8.8
77.2 20.6
77.6 20.7
203.8 40.2
116.2 35.3
59.7 18.3
HDL¼ high-density lipoprotein, LDL¼ low-density lipoprotein,
d as mean standard deviation.
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TABLE 3. Association of Hypertension With Candidate Single Nucleotide Polymorphisms
SNPs Genotype
No.
of NT
No. of
HYP
P Value
HWE
P Value
Codominant Model
P Value
Recessive Model
STK39
rs3754777 CC 592 (68.0) 462 (62.1)
CT 253 (29.0) 228 (30.6)
TT 26 (3.0) 54 (7.3) 0.87 0.0002 <0.0001
rs6749447 TT 415 (51.7) 365 (52.0)
GT 320 (39.9) 284 (40.4)
GG 67 (8.4) 53 (7.6) 0.63 0.85 0.57
rs35929607 TT 551 (65.1) 469 (66.2)
CT 241 (28.5) 186 (26.2)
CC 54 (6.4) 54 (7.6) 0.0002 0.45 0.34
WNK1
rs1468326 CC 639 (74.1) 508 (75.5)
CA 203 (23.6) 128 (19.0)
AA 20 (2.3) 37 (5.5) 0.42 0.0009 0.001
rs765250 AA 407 (46.1) 305 (40.8)
GA 358 (40.5) 317 (42.4)
GG 118 (13.4) 126 (16.8) 0.006 0.04 0.05
HWE¼Hardy-Weinberg equilibrium (controls),HYP¼ hypertensive patients,NT¼ normotensive subjects, SNPs¼ single nucleotide polymorphisms.
Persu et al Medicine  Volume 95, Number 15, April 2016increased in AA (OR: 2.3 [95% CI: 1.3–4.1]) but not in CA
patients (OR: 0.8 [95% CI: 0.6–1.0]), suggesting a recessive
effect. The association was maintained, or even larger in a
model including age, sex, BMI, and total number of antihy-
pertensive drug classes (OR: 4.1 [95% CI: 1.5–11.7])
(Figure 1B). Finally, mean systolic BP was significantly higher
in subjects harboring this genotype compared with CC and CA
subjects (Figure 1E).
Joint Effect of SNPs rs 3754777 (STK39) and
rs1468326 (WNK1)
The distribution of genotypes in patients harboring 0, 1, or 2
of the at-risk genotypes (TT for rs3754777; AA for rs1468326)
was also significantly different (P¼ 0.014) between hypertensive
and normotensive subjects (normotensives: 95.6%, 4.0%, and
0.4% vs hypertensives: 92.1%, 6.8%, and 1.1%, respectively).
Furthermore, in the whole data set, BP increased in a dose-
dependent fashion according to the number of at-risk genotypes
(Figure 1F). Along the same lines, the OR of being hypertensive
tended to increase gradually according to the presence of 0, 1, or 2
at-risk alleles at the homozygous state (1 vs 0: OR: 1.7 [95% CI:
1.1–2.8]; 2 vs 0: OR: 3.1 [95% CI: 0.8–11.9]). The same trend
was observed in the adjusted model (Figure 1C).
DISCUSSION
We looked for an associationbetween hypertension, BP, and
genetic variants of STK39 andWNK1 in the BELHYPGEN case-
control study, including predominantly severe hypertensive
patients. A highly significant, consistent association was found
for 2 of the 5 investigated SNPs, located respectively within the
STK39 gene6 and upstream of the WNK1 promoter.13 Further-
more, despite the moderate sample size, our results suggest a
synergistic effect of the variants. From a pathophysiological
perspective, this fits with WNK1 being a regulator of SPAK,
the product of STK39, which in turn activates the NCC.7–104 | www.md-journal.comThe association of the STK39 variant rs3754777 with
hypertension is in agreement with the results of a GWAS
published by Wang et al,6 one of the first ‘‘success stories’’ in
the field of hypertension and a number of subsequent studies,
recently summarized in a meta-analysis.14 Interestingly, while
our analysis was limited to patients of Caucasian descent, in the
latter, the effect of the STK39 variant was only found in Eur-
opeans and East-Asians, but not in Africans.14 In contrast, we
were not able to replicate the associations with 2 other variants
described in the initial GWAS,6 rs6749447 and rs35929607. In
particular, our findings challenge the hypothesis that rs35929607
is the functional variant responsible for the effect of the ‘‘STK39
locus’’ on BP, whereas rs3754777 is only a surrogate.6 Notably,
this claim rests mostly on indirect evidence based on luciferase
reporter gene constructs.6 The underlying truth may be much
more complex, with several functional polymorphisms jointly
accounting for the overall effect.15
An association between hypertension, BP, and variant
rs1468326, located 3 kb from the promoter of WNK1, was
already reported in severely hypertensive families from the
BRIGHT study.13 Nevertheless, our study differs from the latter
by the less convincing association with another WNK1 variant,
rs765250.16 This discrepancy may reflect a lack of statistical
power, as it was not detected in the first report of the BRIGHT
study,13 but only in the second one, which included a much
larger sample size.16 Notably, even in the latter, the association
with hypertension per se was only borderline significant.16
Along with WNK4, WNK1 regulates numerous ion chan-
nels involved in sodium and potassium transport in the kidney
and in various other epithelia.7–10 Mutations inWNK1 are at the
origin of pseudohypoaldosteronism type II (Gordon syndrome),
characterized by hypertension and hyperkalemia.17 The role of
the WNK-SPAK-NKCC2/NCC pathway is further highlighted
by knockout mice models. In particular, heterozygous knockout
mice for WNK118 or SPAK19 exhibit a hypotensive phenotype.
In addition, homozygous knockout mice, which completely lackCopyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 1. Odds ratios of being hypertensive (A–C) and mean SBP (D–F) according to genotype at rs3754777 and rs1468326. Odds
ratios were adjusted for sex, age, body mass index, and total number of antihypertensive drug classes. The most frequent, wild-type
genotype was used as the reference. In panels C and F, the numbers 0, 1, and 2 on the horizontal refer to homozygosity for theminor, ‘‘at-
risk’’ allele at rs3754777 and rs1468326.

P< axis 0.05. SBP¼ systolic blood pressure level.
Medicine  Volume 95, Number 15, April 2016 STK39, WNK1, and HypertensionSPAK expression, display hypokalemia, hypomagnesemia, and
hypocalciuria (Gitelman-like syndrome) and impaired vasocon-
striction.19 Finally, mice expressing a mutated SPAK, which
cannot be activated by WNK isoforms, show decreased phos-
phorylation and expression of NKCC2 and NCC, and signifi-
cantly lower, salt-dependent BP.20 On a lifelong basis, even
subtle genetic changes leading tomild sodiumandwater accumu-
lation may cause a significant alteration in sodium and water
balance, fluid retention, and subsequent chronic hypertension.21
Although in complex traits such as hypertension, ORs are
typically within the range of 1.1 to 1.3,22 and individual loci
identified in GWAS account for 1mmHgBP atmost,23–25 in our
study, at-risk genotypeswere associatedwith adjustedORs of 4 to
6 and approximately 10mm Hg higher mean BP compared with
wild-type, admittedly with a large confidence interval. Although
these relatively impressive results may be due to chance or some
sort of ‘‘winner’s curse’’ phenomenon,26 they may also result
from inclusion of severe, difficult-to-treat hypertensive patients
with early target organ damage, as expected in a tertiary referralCopyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.cohort. In the latter, the contribution of genetics is expected to be
higher than in late-onset, milder hypertension. Furthermore, the
cases were compared with strictly normotensive, healthy con-
trols. The effectiveness of using cases and controls at the extreme
of the distribution for a continuous trait such as BP (the so-called
‘‘hypercontrols’ strategy’’) is a knownway to decrease noise and
increase statistical power.27,28 Finally, statistical powermay have
been increased by limiting the analysis to patients of
Caucasian descent.
Several limitations of our study should be acknowledged.
The lack of association between rs35929607 and rs765250 and
BP/hypertension should be interpretedwith caution in viewof the
deviation from Hardy-Weinberg equilibrium, possibly reflecting
population stratification, selection bias, unaccounted confound-
ing factors, or, less probably, genotyping errors.29,30 Most
patients (85%)were on antihypertensive treatment. Patients were
recruited in tertiary referral centers, and thus even if replicated
in other, similar cohorts, our findings may not be readily extra-
polated to the overall hypertensive population. The controlwww.md-journal.com | 5
Persu et al Medicine  Volume 95, Number 15, April 2016population was recruited in a single center of occupational health
consultation including mostly health sector employees. As
expected, the prevalence of women was high. Also, patients
>65 years old were by definition excluded, leading to a sub-
stantial age difference between cases and controls. Still, adjust-
ment for sex, age, BMI, and antihypertensive treatment did not
change, and even reinforced our findings. Furthermore, BEL-
HYPGEN is a unique cohort including patients from both the
South and North of Belgium recruited in 6 of 7 Belgian medical
faculties, and is thus likely representative of hypertensive patients
seen at tertiary referral centers, providing reliable information on
genetic epidemiology of this particular subset of at-risk hyper-
tensive patients. Our sample size was of the same order of
magnitude as in other studies with focus on STK396,14 and
WNK1,13 in which multiple SNPs were tested in either gene.
Our results need to be replicated in other clinical settings,
including treatment-naive hypertensive patients in whom inter-
mediary phenotypes, such as plasma renin activity, aldosterone
plasma level, urinary sodium, and fractional sodium excretion,
may be reliably assessed. Furthermore, the impact of variants
located in other genes belonging to the WNK-SPAK-NKCC2/
NCC pathway and other pathways related to water and sodium
reabsorption may deserve to be jointly studied. Finally, unra-
veling the genetic epidemiology of sodium and water reabsorp-
tion in the kidney tubule may help to individualize
antihypertensive treatment and identify new therapeutic targets.
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